- The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria (PH), a rare genetic disorder that mainly affects the kidneys and results from a buildup of a substance called oxalate.
- Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or sold to a third party.
- CHK-336 is currently progressing through IND-enabling studies, with a Phase 1 study planned for the second half of 2021.
- Price Action: KDNY stock is up 3.52% at $15.89 on the last check Tuesday.
- Related News: Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
